Biocon Biologics Inc
1 products tracked · names used in filings: Biocon Biologics Inc
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Thu 12 Nov 2026🇺🇸 FDA approval
FDA approves Pebrilzo (pertuzumab), a new medicine
Biocon Biologics Inc; BLA761501; New biologic; solution · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Pebrilzo pertuzumab | Approved | 2026-11-12 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.